Pharmacological activation of the p53 pathway has been reported for the treatment of skin cancer, neuroblastoma, prostate cancer, and other tumors (Loureiro et al., 2020; Patiño-Morales et al., 2020; Won and Seo, 2020; Zafar et al., 2021). This evidence concerns the gene TP53 and prostate carcinoma.